Consensus Delineation Guidelines for Pelvic Lymph Node Radiation Therapy of Prostate Cancer: On Behalf of the Francophone Group of Urological Radiation Therapy (GFRU).


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 Jan 2024
Historique:
received: 08 03 2023
revised: 01 06 2023
accepted: 14 07 2023
medline: 6 12 2023
pubmed: 29 7 2023
entrez: 28 7 2023
Statut: ppublish

Résumé

Clinical target volume (CTV) delineation for pelvic lymph nodes in prostate cancer is currently based on 3 consensus guidelines with some inherent discrepancies. To improve the reproducibility in nodal delineation, the Francophone Group of Urological Radiotherapy (Groupe Francophone de Radiothérapie Urologique [GFRU]) worked toward proposing an easily applicable, reproducible, and practice-validated contouring guideline for pelvic nodal CTV. The nodal CTV data sets of a high-risk node-negative prostate cancer clinical case contoured by 86 radiation oncologists participating in a GFRU contouring workshop were analyzed. CTV volumes were defined before and after a structured presentation of literature data on lymphatic drainage pathways and patterns of nodal involvement and relapse, illustrated using a reference contour (CRef) defined by 3 GFRU experts. The consistency between the participants' contours and CRef was assessed quantitively by means of the Simultaneous Truth and Performance Level Estimation (STAPLE) method, the Dice coefficient, and the Hausdorff distance and qualitatively using a count map. These results combined with the literature review were thoroughly discussed among GFRU experts to reach a consensus. From the 86 workshop participants, the volume of the STAPLE CTV was 591 cc compared with 502 cc for CRef. The Dice coefficient of the STAPLE CTV compared with the experts' CRef was 0.736 (±0.084) before and 0.823 (±0.070) after the workshop; the standard deviation decreased from 11.5% to 8.5% over the workshop. The Hausdorff distance of the STAPLE CTV compared with the CRef was 34.5 mm (±12.4) before the workshop and 21.8 mm (±9.3) after the workshop. Four areas of significant interobserver variability were identified, and a consensus was reached. Using a robust methodology, our cooperative group proposed an easily applicable, reproducible, and practice-validated guideline for the delineation of the pelvic CTV in prostate cancer, useful for implementation in daily practice and clinical trials.

Identifiants

pubmed: 37506982
pii: S0360-3016(23)07680-0
doi: 10.1016/j.ijrobp.2023.07.020
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

29-40

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Olivier De Hertogh (O)

Radiation Oncology Department, CHR Verviers East Belgium, Verviers, Belgium. Electronic address: olivier.dehertogh@chrverviers.be.

Guillaume Le Bihan (G)

Radiation Oncology Department, Institut Bergonié, Bordeaux, France.

Thomas Zilli (T)

Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Samuel Palumbo (S)

Radiation Oncology Department, Hôpital de Jolimont, La Louvière, Belgium.

Marjory Jolicoeur (M)

Radiation Oncology Department, Charles LeMoyne Hospital, CISSS Montérégie-center, Montréal, Quebec, Canada.

Gilles Crehange (G)

Radiation Oncology Department, Institut Curie, Saint-Cloud, France.

Talar Derashodian (T)

Radiation Oncology Department, Charles LeMoyne Hospital, CISSS Montérégie-center, Montréal, Quebec, Canada.

Guilhem Roubaud (G)

Medical Oncology Department, Institut Bergonié, Bordeaux, France.

Carl Salembier (C)

Radiation Oncology Department, Europe Hospitals Brussels, Brussels, Belgium.

Stéphane Supiot (S)

Radiation Oncology Department, Institut de Cancérologie de l'Ouest, Nantes Saint-Herblain, France; Unité en Sciences Biologiques et Biotechnologies, University of Nantes, Nantes, France.

Olivier Chapet (O)

Radiation Oncology Department, Center Hospitalier Lyon Sud, Pierre Benite, France.

Verane Achard (V)

Faculty of Medicine, University of Geneva, Geneva, Switzerland; Department of Radiation Oncology, HFR Fribourg, Villars-sur-Glâne, Switzerland.

Paul Sargos (P)

Radiation Oncology Department, Institut Bergonié, Bordeaux, France; Department of Radiation Oncology, McGill University Health Centre, Montréal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH